2022
DOI: 10.1007/s12272-022-01423-0
|View full text |Cite
|
Sign up to set email alerts
|

Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(1 citation statement)
references
References 31 publications
0
1
0
Order By: Relevance
“…Moreover, the CYP2C19*17 allele (rs12248560, c.−806C > T) is a mutation present in the 5′-flanking region that increases gene transcription and CYP2C19 activity in vivo (Sim et al 2006). Pharmacokinetic changes caused by genetic polymorphism of the gene encoding the CYP2C19 enzyme have been reported for various drugs (Scott et al 2012;Choi et al 2014;Lee et al 2018;Cho et al 2023).…”
Section: Introductionmentioning
confidence: 99%
“…Moreover, the CYP2C19*17 allele (rs12248560, c.−806C > T) is a mutation present in the 5′-flanking region that increases gene transcription and CYP2C19 activity in vivo (Sim et al 2006). Pharmacokinetic changes caused by genetic polymorphism of the gene encoding the CYP2C19 enzyme have been reported for various drugs (Scott et al 2012;Choi et al 2014;Lee et al 2018;Cho et al 2023).…”
Section: Introductionmentioning
confidence: 99%